Company profile
Matinas BioPharma Holdings, Inc.
AMEX: MTNB · Healthcare · Biotechnology
#864 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
32DFH 26DQ 38GM 36SS 31
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, balance-sheet leverage · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$10.3M
Employees
2
as of 2026-08-24
Market cap
$1.3M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.1M$1.1M2023
Net income-$10.3M-$10.3M2025
Operating income-$7.0M-$7.0M2025
Total assets$7.2M$7.2M2025
Liabilities$2.4M$2.4M2025
Equity$4.8M$4.8M2025
Revenue trend
FY2016 – FY2023 · USD
FY16
FY17
FY19
FY19
FY20
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2020
By product
CFF Research Grant Revenue100%
By geography
Not disclosed.
The read
What is Matinas BioPharma Holdings, Inc.’s revenue?
Matinas BioPharma Holdings, Inc. booked $1.1M in FY2023 revenue, contracting 66% year over year — slower than 85% of Healthcare companies we track, at a -943.9% net margin.
Peers · Healthcare
Bespoke Extracts, Inc.——Kaleido Biosciences, Inc.——White River Energy Corp.——Reflect Scientific, Inc.——First Choice Healthcare Solutions, Inc.26DOrgenesis Inc.——Neighbors
Somerset →Key facts
CEOJerome D. Jabbour
SectorHealthcare
IndustryBiotechnology
HeadquartersBedminster, NJ
ExchangeAMEX: MTNB
Employees2
IPO date2014-07-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.